Physician

David No, MD, PHD

According to 2025 Medicare claims, David No, MD, PHD (NPI: 1366452658) practices dermatology in the Sacramento-Roseville-Folsom, CA market, with the plurality of this provider's patient population coming from El Dorado, CA. This provider's primary affiliated billing organization is GOLDEN STATE DERMATOLOGY ASSOCIATES, INC. (NPI: 1700860871; TIN: 68-0299684) and primary practice location at 95630-4771.

No's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,820 traditional Medicare patients, billed 13,733 HCPCS/CPT codes, and received $897,843 in Medicare payments. The top billing code was 17004 (Destruction of precancer skin growth, 15 or more growths). Part D data shows 1,166 prescription claims across 515 beneficiaries totaling $573,367 in drug costs, led by Taltz Autoinjector (Ixekizumab). Open Payments data shows 62 records totaling $1,278. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $157,647 to $573,367. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$452K$903K2015 Medicare payment: $746,103 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $788,634 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $777,878 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $807,519 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $870,170 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $783,381 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $843,997 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $847,378 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $903,227 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $897,843 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20152,12912,260$746,103
20161,98412,347$788,634
20171,98612,116$777,878
20182,03013,002$807,519
20192,06914,084$870,170
20201,94313,716$783,381
20212,15814,822$843,997
20221,95814,741$847,378
20231,76514,359$903,227
20241,82013,733$897,843

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$371K$741K2015 Drug cost: $157,647 (USD; Tot_Drug_Cst)2016 Drug cost: $151,179 (USD; Tot_Drug_Cst)2017 Drug cost: $197,295 (USD; Tot_Drug_Cst)2018 Drug cost: $229,723 (USD; Tot_Drug_Cst)2019 Drug cost: $317,675 (USD; Tot_Drug_Cst)2020 Drug cost: $291,216 (USD; Tot_Drug_Cst)2021 Drug cost: $349,390 (USD; Tot_Drug_Cst)2022 Drug cost: $643,199 (USD; Tot_Drug_Cst)2023 Drug cost: $741,454 (USD; Tot_Drug_Cst)2024 Drug cost: $573,367 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20154701,012$157,647
2016470965$151,179
2017482991$197,295
20184921,050$229,723
20195181,060$317,675
2020458921$291,216
20215001,017$349,390
20224531,025$643,199
2023415964$741,454
20245151,166$573,367

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17004Destruction of precancer skin growth, 15 or more growths394557$138
11102Biopsy of related skin growth, first growth8081,045$79
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more1,4522,076$65
17000Destruction of precancer skin growth, 1 growth8571,046$40
17003Destruction of precancer skin growth, 2-14 growths7245,539$6

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Taltz AutoinjectorIxekizumab14392$94,912
Humira PenAdalimumab12336$81,648
Dupixent PenDupilumab12336$45,276
AcitretinAcitretin14420$6,335
TacrolimusTacrolimus411,236$6,251

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.62$1,278ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for David No, MD, PHD?

Tedicare shows public-source Medicare data for David No, MD, PHD (NPI 1366452658), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David No, MD, PHD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to David No, MD, PHD?

David No, MD, PHD is linked to GOLDEN STATE DERMATOLOGY ASSOCIATES, INC. (billing NPI 1700860871) in the available physician profile data.

Does David No, MD, PHD have Open Payments data?

David No, MD, PHD has 62 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.